» Articles » PMID: 36057635

Prevalence and Significance of Incidental Findings on 68 Ga-DOTA-conjugated Somatostatin Receptor-targeting Peptide PET/CT: a Systematic Review of the Literature

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2022 Sep 3
PMID 36057635
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: We aimed to evaluate the prevalence of incidental  Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy.

Materials And Methods: Studies reporting incidental SSTR PET/CT findings were systematically searched in PubMed, Cochrane, Embase and Web of Science literature published prior to 1 of May 2020. Studies were filtered by two independent readers for eligibility based on title and abstract, and subsequently on full text. The main exclusion criteria were: 1) pathological findings that matched scan indication, 2) known organ specific disease and/or incidental findings confirmed on other scan modality prior to SSTR PET/CT, 3) lack of diagnosis and/or follow up, and 4) results published in proceedings or conference abstracts.

Results: Twenty-one studies, comprising a total of 2906 subjects, were eligible for the analysis. Studies included were retrospective cohort studies on incidental SSTR PET/CT findings in a specific organ (n = 2888, 7/21) or case reports (n = 18, 14/21). A total of 133 subjects had incidental SSTR PET/CT findings. Incidental findings were predominantly seen in the thyroid gland (n = 65), spine (n = 30), brain (n = 26) and breast (n = 6). Seventeen of 133 (13%) incidental findings were malignant on final diagnosis. Incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually.

Conclusion: The most incidental SSTR PET/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET/CT and in the counseling of clinicians.

Citing Articles

Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.

Luo J, Bahlis N, Chan D, Duggan P, Jimenez-Zepeda V, Lee H Curr Oncol. 2024; 31(12):7445-7458.

PMID: 39727673 PMC: 11674242. DOI: 10.3390/curroncol31120550.


Abnormal uptake related to the thyroid gland on somatostatin receptor-targeted PET imaging: reported prevalence and rate of thyroid malignancy and parathyroid adenomas.

Sjostedt S, Hahn C, Rasmussen A, Oturai P, Cramon P Endocr Connect. 2024; 13(12).

PMID: 39579473 PMC: 11623246. DOI: 10.1530/EC-24-0419.


Crown-hydroxylamines are pH-dependent chelating N,O-ligands with a potential for aerobic oxidation catalysis.

Lesnikov V, Golovanov I, Nelyubina Y, Aksenova S, Sukhorukov A Nat Commun. 2023; 14(1):7673.

PMID: 37996433 PMC: 10667252. DOI: 10.1038/s41467-023-43530-6.


Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands.

Johnson F, Hofauer B, Wirth M, Wollenberg B, Stogbauer F, Notohamiprodjo S Cancers (Basel). 2023; 15(15).

PMID: 37568733 PMC: 10417029. DOI: 10.3390/cancers15153917.


Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms.

Adnan A, Basu S Diagnostics (Basel). 2023; 13(13).

PMID: 37443548 PMC: 10341107. DOI: 10.3390/diagnostics13132154.

References
1.
Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B . 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(4):514-23. DOI: 10.1007/s00259-012-2309-3. View

2.
Gedberg N, Karmisholt J, Gade M, Fisker R, Iyer V, Petersen L . The Frequency of Focal Thyroid Incidental Findings and Risk of Malignancy Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography in an Iodine Deficient Population. Diagnostics (Basel). 2018; 8(3). PMC: 6165051. DOI: 10.3390/diagnostics8030046. View

3.
Mahajan S, Shaha A, Grewal R . Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases. Clin Nucl Med. 2017; 43(2):136-138. PMC: 5752440. DOI: 10.1097/RLU.0000000000001950. View

4.
Prasad V, Baum R . Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010; 54(1):61-7. View

5.
Law W, Fiumara F, Fong W, Macfarlane D . The 'double pituitary hot spot' sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET. J Med Imaging Radiat Oncol. 2013; 57(6):680-3. DOI: 10.1111/1754-9485.12069. View